CD40 and prostate cancer: The approach has potential to be effective across different tumor types, since the neoantigens generated in vivo by RT are tumor/patient specific, and the anti-CD40 can act on APCs present in the tumor microenvironment without the need for the tumor to express CD40 as with invasive prostate cancer (3, 10, 11).